Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Zelgen’s DLL3 trispecific goes pivotal
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Servier eyes up Ideaya’s darovasertib
As pivotal data approach, the French group pays $210m for ex-US rights.
BeOne cashes in its Imdelltra royalty
Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.
KAT6 catalysts to kick off 2025
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
